Cargando…

Establishment and clinical validation of an in-cell-ELISA-based assay for the rapid quantification of Rabies lyssavirus neutralizing antibodies

Neutralizing antibodies (nAbs) prevent the entry of viruses into permissive cells. Since nAbs represent correlates of protection against the Rabies lyssavirus, the presence of sufficient nAbs indicates effective vaccination. Accordingly, Rabies lyssavirus-specific nAb titers need to be determined in...

Descripción completa

Detalles Bibliográficos
Autores principales: Schöler, Lara, Le-Trilling, Vu Thuy Khanh, Dittmer, Ulf, Fiedler, Melanie, Trilling, Mirko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159627/
https://www.ncbi.nlm.nih.gov/pubmed/35536867
http://dx.doi.org/10.1371/journal.pntd.0010425
_version_ 1784719096108023808
author Schöler, Lara
Le-Trilling, Vu Thuy Khanh
Dittmer, Ulf
Fiedler, Melanie
Trilling, Mirko
author_facet Schöler, Lara
Le-Trilling, Vu Thuy Khanh
Dittmer, Ulf
Fiedler, Melanie
Trilling, Mirko
author_sort Schöler, Lara
collection PubMed
description Neutralizing antibodies (nAbs) prevent the entry of viruses into permissive cells. Since nAbs represent correlates of protection against the Rabies lyssavirus, the presence of sufficient nAbs indicates effective vaccination. Accordingly, Rabies lyssavirus-specific nAb titers need to be determined in routine diagnostics to identify individuals being at risk of Rabies lyssavirus infections due to insufficient immunity. The current gold standard for the quantification of Rabies lyssavirus-specific nAbs is the rapid fluorescent focus inhibition test (RFFIT). However, RFFITs are expensive and labor-intensive since multiple microplate wells must be evaluated one-by-one by trained personnel through microscopic inspection, which limits the number of samples that can be processed. To overcome this disadvantage, we established a novel assay for Rabies lyssavirus-specific nAbs relying on an in-cell-ELISA (icELISA)-based neutralization test (icNT). The icNT differs from the RFFIT in the readout phase, and can be automatically quantified in minutes using broadly available microplate readers. During the establishment, icNT parameters such as antibody concentrations, permeabilization procedures, blocking reagents, infectious doses, and the duration of infection were optimized. Afterwards, a dose-dependent detection of Rabies lyssavirus neutralization was demonstrated using the WHO Standard Rabies Immunoglobulin reference. A panel of 200 sera with known RFFIT titers revealed very good sensitivity and specificity of the icNT. Furthermore, the icNT showed very good intra- and inter-assay precision. By recognizing Rabies lyssavirus-specific antigens, the assay can be applied immediately to automatically quantify the concentration of Rabies lyssavirus nAbs in routine diagnostics or for various basic research questions such as screening for antiviral compounds.
format Online
Article
Text
id pubmed-9159627
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-91596272022-06-02 Establishment and clinical validation of an in-cell-ELISA-based assay for the rapid quantification of Rabies lyssavirus neutralizing antibodies Schöler, Lara Le-Trilling, Vu Thuy Khanh Dittmer, Ulf Fiedler, Melanie Trilling, Mirko PLoS Negl Trop Dis Research Article Neutralizing antibodies (nAbs) prevent the entry of viruses into permissive cells. Since nAbs represent correlates of protection against the Rabies lyssavirus, the presence of sufficient nAbs indicates effective vaccination. Accordingly, Rabies lyssavirus-specific nAb titers need to be determined in routine diagnostics to identify individuals being at risk of Rabies lyssavirus infections due to insufficient immunity. The current gold standard for the quantification of Rabies lyssavirus-specific nAbs is the rapid fluorescent focus inhibition test (RFFIT). However, RFFITs are expensive and labor-intensive since multiple microplate wells must be evaluated one-by-one by trained personnel through microscopic inspection, which limits the number of samples that can be processed. To overcome this disadvantage, we established a novel assay for Rabies lyssavirus-specific nAbs relying on an in-cell-ELISA (icELISA)-based neutralization test (icNT). The icNT differs from the RFFIT in the readout phase, and can be automatically quantified in minutes using broadly available microplate readers. During the establishment, icNT parameters such as antibody concentrations, permeabilization procedures, blocking reagents, infectious doses, and the duration of infection were optimized. Afterwards, a dose-dependent detection of Rabies lyssavirus neutralization was demonstrated using the WHO Standard Rabies Immunoglobulin reference. A panel of 200 sera with known RFFIT titers revealed very good sensitivity and specificity of the icNT. Furthermore, the icNT showed very good intra- and inter-assay precision. By recognizing Rabies lyssavirus-specific antigens, the assay can be applied immediately to automatically quantify the concentration of Rabies lyssavirus nAbs in routine diagnostics or for various basic research questions such as screening for antiviral compounds. Public Library of Science 2022-05-10 /pmc/articles/PMC9159627/ /pubmed/35536867 http://dx.doi.org/10.1371/journal.pntd.0010425 Text en © 2022 Schöler et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Schöler, Lara
Le-Trilling, Vu Thuy Khanh
Dittmer, Ulf
Fiedler, Melanie
Trilling, Mirko
Establishment and clinical validation of an in-cell-ELISA-based assay for the rapid quantification of Rabies lyssavirus neutralizing antibodies
title Establishment and clinical validation of an in-cell-ELISA-based assay for the rapid quantification of Rabies lyssavirus neutralizing antibodies
title_full Establishment and clinical validation of an in-cell-ELISA-based assay for the rapid quantification of Rabies lyssavirus neutralizing antibodies
title_fullStr Establishment and clinical validation of an in-cell-ELISA-based assay for the rapid quantification of Rabies lyssavirus neutralizing antibodies
title_full_unstemmed Establishment and clinical validation of an in-cell-ELISA-based assay for the rapid quantification of Rabies lyssavirus neutralizing antibodies
title_short Establishment and clinical validation of an in-cell-ELISA-based assay for the rapid quantification of Rabies lyssavirus neutralizing antibodies
title_sort establishment and clinical validation of an in-cell-elisa-based assay for the rapid quantification of rabies lyssavirus neutralizing antibodies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159627/
https://www.ncbi.nlm.nih.gov/pubmed/35536867
http://dx.doi.org/10.1371/journal.pntd.0010425
work_keys_str_mv AT scholerlara establishmentandclinicalvalidationofanincellelisabasedassayfortherapidquantificationofrabieslyssavirusneutralizingantibodies
AT letrillingvuthuykhanh establishmentandclinicalvalidationofanincellelisabasedassayfortherapidquantificationofrabieslyssavirusneutralizingantibodies
AT dittmerulf establishmentandclinicalvalidationofanincellelisabasedassayfortherapidquantificationofrabieslyssavirusneutralizingantibodies
AT fiedlermelanie establishmentandclinicalvalidationofanincellelisabasedassayfortherapidquantificationofrabieslyssavirusneutralizingantibodies
AT trillingmirko establishmentandclinicalvalidationofanincellelisabasedassayfortherapidquantificationofrabieslyssavirusneutralizingantibodies